Citations

Clear

1099 citation(s) found for "Lewis, B".

Determination of hepatitis B phenotype using biochemical and serological markers
Bisceglie, Adrian M. Di , Lombardero, M. , Teckman, Jeffrey , Roberts, Lewis R. , Janssen, Harry L.A. , Belle, Steven H., Hoofnagle, Jay H., Chang, Kyong‐Mi , Ghany, Marc G. , Khalili, Mandana , Roberts, Lewis R , Chang, Kyong-Mi , Khalili, Mandana

Mayo Clinic

Journal of Viral Hepatitis | December 5, 2016 | Volume: 24 | Issue: 4 | Pages: 320-329

10.1111/jvh.12643 | PMID 27917600 Get It

AbstractThe aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determining the need for antiviral therapy. We assessed the phenotype of hepatitis B of 1,390 adult participants enrolled in the Hepatitis B Research Network Cohort Study, using a computer algorithm. Only 4% were immune tolerant, while 35% had chronic hepatitis B (18% e antigen positive and 17% e antigen negative) while 23% were inactive carriers. Strikingly, 38% of participants did not fit clearly into any one of these groups and were considered indeterminant. The largest subset of indeterminants had elevated serum aminotransferases with low levels of HBV DNA (less than 10,000 iu/mL). Subsequent determination of hepatitis B phenotype on the next available laboratory tests showed that 64% remained indeterminant. These findings call into question the validity of conventional staging of hepatitis B, in large part because of the substantial proportion of patients who do not fit readily into one of the usual stages or phases. Further studies are needed of the indeterminant category of chronic hepatitis B viral infection, including assessments of whether patients in this group are perhaps in transition to another phase or if they are a distinct phenotype with a need to assess liver disease severity and need for antiviral therapy. (ClinicalTrials.gov identifier NCT01263587).
Vascularized appendicular lymph node transfer for treatment of extremity lymphedema: A case report
Ciudad, Pedro , Manrique, Oscar J. , Date, Shivprasad , Chang, Wei‐Ling , Nicoli, Fabio , Sapountzis, Stamatis , Cheng, Hsu‐Tang , Agko, Mouchammed , Chen, Hung‐Chi , Roberts, Lewis R. , Chen, Hung‐Chi , Roberts, Lewis R , Cheng, Hsu-Tang , Mouchammed, Agko

Mayo Clinic

Microsurgery | December 2, 2016 | Volume: 38 | Issue: 5 | Pages: 553-557

10.1002/micr.30134 | PMID 27911477 Get It

AbstractVascularized lymph node transfer has demonstrated promising results for the treatment of extremity lymphedema. In an attempt to find the ideal donor site, several vascularized lymph nodes have been described. Each has a common goal of decreasing morbidity and avoiding iatrogenic lymphedema while obtaining good clinical results. Herein, we present the preliminary clinical outcomes of an intra‐abdominal lymph node flap option based on the appendicular artery and vein used for the treatment of extremity lymphedema. A 62 year‐old woman with moderate lower extremity lymphedema, on chronic antibiotics because of recurrent infections and unsatisfactory outcomes after conservative treatment underwent a vascularized appendicular lymph node (VALN) transfer. At a follow‐up of 6 months, the reduction rate of the limb circumference was 17.4%, 15.1%, 12.0% and 9% above the knee, below the knee, above the ankle and foot respectively. In addition, no further episodes of infection or other complications were reported after VALN transfer. Postoperative lymphoscintigraphy demonstrated that the VALN flap was able to improve the lymphatic drainage of the affected limb. According to our findings, the use of VALN transfer minimizes donor‐site morbidity, avoids iatrogenic lymphedema and may provide a strong clearance of infection because of the strong immunologic properties of the appendiceal lymphatic tissue in selected patients. Despite these promising results, further research with larger number of patients and longer follow‐ up is needed.
Negligible Thyroid Hormone Content Present in Nonprescription U.S. Weight Loss Products
Seger, Christian, He, Xuemei , Bernet, Victor , Rhee, Connie M. , Leung, Angela M. , Bernet, Victor J, Braverman, Lewis E. , Yeh, Michael W. , Singh, Ravinder J. , Leung, Angela M

Mayo Clinic

Thyroid® | November 29, 2016 | Volume: 27 | Issue: 2 | Pages: 300-301

10.1089/thy.2016.0534 | PMID 27897088 Get It

Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma
Chen, Gang , Nakamura, Ikuo , Dhanasekaran, Renumathy , Iguchi, Eriko , Tolosa, Ezequiel J. , Romecín, Paola , Vera, Renzo E., Almada, Luciana L. , Miamen, Alexander G., Chaiteerakij, Roongruedee , Zhou, Mengtao , Moser, Catherine D., Han, Shaoshan , Hu, Chunling , Banini, Bubu A. , Oseini, Abdul M., Fang, Yong , Yang, Dongye , Shaleh, Hassan M., Wang, Shaoqing , Wu, Dehai, Song, Tao , Lee, Ju‐Seog , Thorgeirsson, Snorri S., Chevet, Éric , Shah, Vijay H. , Fernández-Zapico, Martín E. , Roberts, Lewis R. , Romecin, Paola A, Asiedu, Michael K. , Chen, Yichun, Nakamura, Ikuo, Chaiteerakij, Roongruedee , Chen, Yi‐Chun , Roberts, Lewis R , Dhanasekaran, Renumathy , Hu, Chunling , Chen, Gang , Chevet, Eric

Mayo Clinic

Cancer Research | November 21, 2016 | Volume: 77 | Issue: 3 | Pages: 632-645

10.1158/0008-5472.can-15-2556 | PMID 27872089 Get It

Abstract Existing antiangiogenic approaches to treat metastatic hepatocellular carcinoma (HCC) are weakly effectual, prompting further study of tumor angiogenesis in this disease setting. Here, we report a novel role for sulfatase 2 (SULF2) in driving HCC angiogenesis. Sulf2-deficient mice (Sulf2 KO) exhibited resistance to diethylnitrosamine-induced HCC and did not develop metastases like wild-type mice (Sulf2 WT). The smaller and less numerous tumors formed in Sulf2 KO mice exhibited a markedly lower microvascular density. In human HCC cells, SULF2 overexpression increased endothelial proliferation, adhesion, chemotaxis, and tube formation in a paracrine fashion. Mechanistic analyses identified the extracellular matrix protein periostin (POSTN), a ligand of αvβ3/5 integrins, as an effector protein in SULF2-induced angiogenesis. POSTN silencing in HCC cells attenuated SULF2-induced angiogenesis and tumor growth in vivo. The TGFβ1/SMAD pathway was identified as a critical signaling axis between SULF2 and upregulation of POSTN transcription. In clinical HCC specimens, elevated levels of SULF2 correlated with increased microvascular density, POSTN levels, and relatively poorer patient survival. Together, our findings define an important axis controlling angiogenesis in HCC and a mechanistic foundation for rational drug development. Cancer Res; 77(3); 632–45. ©2016 AACR.
High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver
Zhou, Dan , Hlady, Ryan A. , Schafer, Marissa , White, Thomas A. , Liu, Chen , Choi, Jeong‐Hyeon , Miller, Jordan D. , Roberts, Lewis R. , LeBrasseur, Nathan K. , Robertson, Keith D. , Schafer, Marissa J, Roberts, Lewis R , Robertson, Keith D , LeBrasseur, Nathan K , Schafer, Marissa J , Liu, Chen , Miller, Jordan

Mayo Clinic

Epigenetics | November 18, 2016 | Volume: 12 | Issue: 1 | Pages: 55-69

10.1080/15592294.2016.1261239 | PMID 27858497 Get It

Reply
Chaiteerakij, Roongruedee , Roberts, Lewis R. , Roberts, Lewis R , Choi, Jonggi , Chaiteerakij, Roongruedee

Mayo Clinic

Hepatology | November 5, 2016 | Volume: 65 | Issue: 4 | Pages: 1422-1423

10.1002/hep.28922 | PMID 28032640 Get It

Low Body Mass Index, Serum Creatinine, and Cause of Death in Patients Undergoing Percutaneous Coronary Intervention
Gulati, Rajiv , Reeder, Guy S., Lennon, Ryan J. , Lewis, Bradley R., Behfar, Atta , Sandhu, Gurpreet S. , Rihal, Charanjit S. , Goel, Kashish , Rihal, Charanjit S. , Singh, Mandeep , Behfar, Atta

Mayo Clinic

Journal of the American Heart Association | November 1, 2016 | Volume: 5 | Issue: 11 | Pages: No page available

10.1161/jaha.116.003633 | PMID 27799234 Get It

Background Low body mass index ( BMI ) and serum creatinine are surrogate markers of frailty and sarcopenia. Their relationship with cause‐specific mortality in elderly patients undergoing percutaneous coronary intervention is not well studied. Methods and Results We determined long‐term cardiovascular and noncardiovascular mortality in 9394 consecutive patients aged ≥65 years who underwent percutaneous coronary intervention from 2000 to 2011. BMI and serum creatinine were divided into 4 categories. During a median follow‐up of 4.2 years (interquartile range 1.8–7.3 years), 3243 patients (33.4%) died. In the multivariable model, compared with patients with normal BMI , patients with low BMI had significantly increased all‐cause mortality (hazard ratio [ HR ] 1.4, 95% CI 1.1–1.7), which was related to both cardiovascular causes (HR 1.4, 95% CI 1.0–1.8) and noncardiovascular causes (HR 1.4, 95% CI 1.06–1.9). Compared with normal BMI , significant reduction was noted in patients who were overweight and obese in terms of cardiovascular mortality (overweight: HR 0.77, 95% CI 0.67–0.88; obese: HR 0.80, 95% CI 0.70–0.93) and noncardiovascular mortality (overweight: HR 0.85, 95% CI 0.74–0.97; obese: HR 0.82, 95% CI 0.72–0.95). In a multivariable model, in patients with normal BMI , low creatinine (≤0.70 mg/dL) was significantly associated with increased all‐cause mortality (HR 1.8, 95% CI 1.3–2.5) and cardiovascular mortality (HR 2.3, 95% CI 1.4–3.8) compared with patients with normal creatinine (0.71–1.0 mg/dL); however, this was not observed in other BMI categories. Conclusions We identified a new subgroup of patients with low serum creatinine and normal BMI that was associated with increased all‐cause mortality and cardiovascular mortality in elderly patients undergoing percutaneous coronary intervention. Low BMI was associated with increased cardiovascular and noncardiovascular mortality. Nutritional support, resistance training, and weight‐gain strategies may have potential roles for these patients undergoing percutaneous coronary intervention.
Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage
Fortune, Brett E. , García–Tsao, Guadalupe , Deng, Yanhong , Fallon, Michael B. , Sigal, Samuel H. , Chalasani, Naga , Lim, Joseph K. , Reuben, Adrian , Vargas, Hugo E. , Abrams, Gary A. , Lewis, Michele D. , Hassanein, Tarek , Trotter, James F. , Beavers, Kimberly L. , Ganger, Daniel , Thuluvath, Paul J. , Grace, Norman D., Groszmann, Roberto J., Ciarleglio, Maria , Sanyal, Arun J. , Vargas, Hugo E , Lewis, Michele D

Mayo Clinic

Journal of Clinical Gastroenterology | October 25, 2016 | Volume: 51 | Issue: 5 | Pages: 446-453

10.1097/mcg.0000000000000733 | PMID 27779613 Get It

Goals/Background: Data on acute variceal hemorrhage (AVH) in the United States is limited and the best method to stratify risk is not clear. Taking advantage of a prospective US cohort study, we aimed to (1) describe clinical outcomes of AVH and their predictors; (2) compare predictors of 6-week mortality. Study: Prospective 15-center US cohort of patients with cirrhosis presenting with endoscopically proven AVH, all of whom received antibiotics, vapreotide (a somatostain analog) infusion and endoscopic band ligation. Patients were enrolled between August 2006 and April 2008. Primary outcome was 6-week mortality. Secondary outcome was 5-day treatment failure. The prognostic value of Child-Turcotte-Pugh (CTP) class, Model for End-stage Liver Disease (MELD) score and a recent recalibrated MELD were compared. Results: Seventy eligible patient were enrolled; 18 (26%) patients died within 6-weeks of index bleed. Demographic, clinical, and laboratory data were compared between survivors and nonsurvivors. Multivariate models showed that admission CTP or the MELD score (separately) were independent predictors of survival. The discriminative values of CTP (area under receiver operating characteristic: 0.75) and MELD (area under receiver operating characteristic: 0.79) were good and not significantly different (P=0.27). However, calibration (correlation between observed and predicted mortality) test was significantly better for CTP than for MELD, with the recently described recalibrated MELD model having the worst agreement. Predicted mortality for CTP-A was <10%, CTP-B 10% to 30%; and CTP-C >33%. Conclusions: AVH mortality of 26% in the United States is in the upper range limit compared with recent series but may be due to inclusion of patients with more advanced cirrhosis. CTP score has the best overall performance in the prediction of 6-week mortality and is best at stratifying risk.
Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma
Chang, Anne Lynn S. , Lewis, Karl D. , Arron, Sarah T. , Migden, Michael R. , Yoo, Simon , Day, Bann‐Mo, McKenna, Edward , Sekulić, Aleksandar , Solomon, James A.

Mayo Clinic

Oncotarget | October 14, 2016 | Volume: 7 | Issue: 46 | Pages: 76118-76124

10.18632/oncotarget.12660 | PMID 27764798 Get It

Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5‐Fluorouracil Sensitivity in an East African Population
Elraiyah, Tarig, Jerde, Calvin R. , Shrestha, Shikshya , Wu, Rongmei , Nie, Q, Giama, NH, Sarangi, Vivekananda , Roberts, Lewis R. , Offer, SM, Diasio, RB, Offer, Steven M. , Nie, Qian , Wu, R, Nie, Q, Roberts, Lewis R , Offer, Steven M

Mayo Clinic

Clinical Pharmacology & Therapeutics | October 13, 2016 | Volume: 101 | Issue: 3 | Pages: 382-390

10.1002/cpt.531 | PMID 27727460 Get It

Clinical studies have identified specific genetic variants in dihydropyrimidine dehydrogenase (DPD; DPYD gene) as predictors of severe adverse toxicity to the commonly used chemotherapeutic 5‐fluorouracil (5‐FU); however, these studies have focused on European and European‐American populations. Our laboratory recently demonstrated that additional variants in non‐European haplotypes are predictive of 5‐FU toxicity. The objective of this study was to identify potential risk variants in an understudied East African population relevant to our institution's catchment area. The DPYD protein‐coding region was sequenced in 588 individuals of Somali or Kenyan ancestry living in central/southeast Minnesota. Twelve novel nonsynonymous variants were identified, seven of which significantly decreased DPD activity in vitro. The commonly reported toxicity‐associated variants, *2A, D949V, and I560S, were not detected in any individuals. Overall, this study demonstrates a critical limitation in our knowledge of pharmacogenetic predictors of 5‐FU toxicity, which has been based on clinical studies conducted in populations of limited diversity.